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Abstract
Objective—To identify current outpatient parenteral antibiotic therapy practice patterns and 
complications.
Methods—We administered an 11 question survey to adult infectious disease physicians 
participating in the Emerging Infections Network (EIN), a CDC-sponsored sentinel event 
surveillance network in North America. The survey was distributed electronically or via facsimile 
in November and December 2012. Respondent demographic characteristics were obtained from 
EIN enrollment data.
Results—Overall, 555 (44.6%) of EIN members responded to the survey with 450 (81%) 
indicating they treated ≥ 1 patient with OPAT during an average month. ID consultation was 
reported to be required for a patient to be discharged on OPAT by 99 (22%) respondents. Inpatient 
(282/449; 63%) and outpatient (232/449; 52%) ID physicians were frequently identified as being 
responsible for monitoring lab results. Only 26% (118/448) had dedicated OPAT teams at their 
clinical site. Few ID physicians have systems to track errors, adverse events or “near-misses” 
associated with OPAT (97/449; 22%). OPAT complications were perceived to be rare. Among 
respondents, 80% reported line occlusion/clotting as the most common complication (occurring in 
≥6% of patients), followed by nephrotoxicity and rash (each reported by 61%). Weekly lab 
monitoring of patients on vancomycin was reported by 77% (343/445) of respondents; whereas 
19% (84/445) of respondents reported twice weekly lab monitoring for these patients.
Conclusions—Although utilization of OPAT is common, there is significant variation in 
practice patterns. More uniform OPAT practices may enhance patient safety.
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Introduction
Over the past 30 years, outpatient parenteral antimicrobial therapy (OPAT) has gained in 
popularity as a cost-effective strategy for treating a variety of infectious diseases including 
skin and soft tissue infections1, 2, osteomyelitis3, 4, prosthetic joint infections5 6, and 
endocarditis7. In a 2006 survey of infectious disease physicians, 94% indicated that patients 
are commonly set up for OPAT at hospital discharge.8 In addition to patients’ preference for 
being treated outside the hospital setting9, there are clear cost savings associated with 
OPAT. Use of OPAT is significantly less expensive than continued inpatient care.10–12
In 2004, the Infectious Disease Society of America (IDSA) published practice guidelines 
suggesting standards for OPAT practices. These guidelines provide recommendations on 
patient evaluation and selection for OPAT services, antibiotic selection and administration, 
OPAT team structure, and laboratory monitoring.13 A survey of infectious disease (ID) 
physicans prior to the publication of these guidelines revealed diverse OPAT practices.8 
Little is known about OPAT practice patterns, complication rates and safety systems since 
the publication of these guidelines. The aim of this study was to survey adult infectious 
disease physicians on their current OPAT practices.
Methods
The Emerging Infections Network is a network of ID physicians in North America who 
provide care to adult and pediatric patients. The network was established in 1995 by the 
Centers for Disease Control and Prevention (CDC) to establish a provider-based emerging 
infections sentinel network.14 The network is also used for surveys of current knowledge 
and practices of providers. This survey was sent electronically or via facsimile to the 1244 
EIN members who provide care to adult patients. The survey was conducted from 
November to December 2012. After the survey distribution, email reminders were sent to 
non-respondents 2 and 4 weeks after the initial invitation. The survey consisted of brief 
introductory text and 11 questions. Survey questions addressed OPAT practice patterns and 
safety issues. Participants were asked about their participation in OPAT services, and the 
role of ID consultation prior to discharge or placement of a vascular catheter for designated 
OPAT recipients. Participants were also asked about who was responsible for monitoring 
and acting upon laboratory results from patients receiving OPAT. Respondents were queried 
on their perceptions of the frequency and consequences of OPAT-related complications 
including lab abnormalities, catheter-associated complications and the development of 
Clostridium difficile or bloodstream infections. One question focused on barriers to 
providing safe OPAT services to patients. Finally, participants were asked to indicate the 
frequency of laboratory monitoring during OPAT for several frequently used antibiotics. 
The survey may be found at http://ein.idsociety.org/surveys/survey/62/. Differences in 
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frequencies were analyzed for statistical significance using χ2 tests, Student’s t-test and 
Mann-Whitney U-test as appropriate. A P-value of <0.05 was considered significant.
Results
Overall, 555 (44.6%) of 1244 physicians participating in EIN responded to the survey. 
Respondents came from all US Census regions.15 Response rates were similar across all 
Census regions. Respondents were significantly more likely than non-respondents to have ≥ 
15 years of infectious diseases experience (p<0.0001). EIN members with ≥ 25 years of 
experience were the largest group of respondents (150/274; 55%), followed by those with 
15–24 years of experience (147/292; 50%).
Among respondents, 105 (19%) did not provide care to any patients discharged on OPAT in 
an average month. Among those that did manage patients on OPAT, monthly patient volume 
varied widely; 114 respondents (20%) managed 1–5 patients/month, 214 respondents (39%) 
managed 6–15 patients/month, 80 respondents (14%) managed 16–25 patients/month and 42 
(8%) respondents managed >25 patients/month. Respondents ranked the patient’s home as 
the most common location for receiving OPAT followed by infusion centers, dialysis centers 
and emergency rooms.
Twenty-two percent of respondents reported that ID consultation is required to discharge 
any patient on IV antibiotics. Of those requiring ID consultation to discharge a patient on 
OPAT, only 28 (28%) required ID to approve vascular access placement for OPAT. The 
inpatient (63%) and outpatient (52%) ID physicians were the most commonly identified as 
being responsible for monitoring and acting upon laboratory results. Ninety-four 
respondents (21%) indicated the patient’s primary care physician was responsible for 
monitoring laboratory results. Dedicated OPAT teams whose primary job is to monitor 
patients on OPAT were uncommon with 118 (26%) reporting this service at their primary 
hospital or clinic. Respondents providing OPAT services to ≥16 patients per month were 
more likely to have a dedicated OPAT team compared to lower volume providers (40% vs 
21%, p <.001). Lack of a dedicated OPAT team was the single most common barrier 
reported to providing safe OPAT services (median rank 2), followed by the large number of 
locations patients receive OPAT, communication issues, and volume of laboratory results 
(median rank 3).
Only 22% (97) of respondents have a system to track the frequency of errors, adverse events 
or “near-misses” associated with OPAT. Those providing OPAT services to >16 patients per 
month were more likely to have error reporting systems than lower volume providers (32% 
vs 18%, p=.023). Line occlusion or clotting, rash and nephrotoxicity were the most 
commonly reported complications associated with OPAT (Figure 1). Respondents indicated 
that patients commonly required line exchange or removal or change in antibiotic therapy 
due to complications from OPAT; hospitalization for OPAT complications was less 
common (Figure 2). Over the past 5 years, 22% (98) and 48% (214) of respondents reported 
OPAT-related complications to be less frequent or unchanged, respectively. A minority (67; 
15%) reported OPAT-related complications to be more frequent than five years ago. 
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Although there is some variation, weekly laboratory monitoring was reported to be the most 
common practice for several common antibiotics (Table 1).
Discussion
We report the results of a survey of a large network of adult infectious diseases physicians 
regarding their experiences providing OPAT. We found that the utilization of OPAT is 
common among ID physicians with over 80% of respondents discharging ≥ 1 patient on 
OPAT during an average month. We found significant variability in involvement of ID 
physicians in selecting patients for OPAT, practice infrastructure and laboratory monitoring 
practices.
Selecting patients who would benefit from OPAT is critical to treatment success. 
International OPAT guidelines recommend careful review of patients who might be 
appropriate for OPAT.13, 16 Patients discharged on OPAT must be medically stable to 
receive continued treatment outside the inpatient hospital setting. In addition, IDSA 
guidelines recommend an assessment of the patient and caregivers who will be responsible 
for administering the medications and caring for vascular access devices.13 In addition to 
assessing the patient and caregiver’s ability to provide daily OPAT care at home, formal ID 
consultation facilitates the appropriate selection of antibiotic therapy. Sharma et al. found 
that requiring ID consultation prior to discharge on OPAT frequently altered the patient’s 
care and resulted in a significant cost savings.17 At the Cleveland Clinic, ID consultation is 
required prior to patient discharge on OPAT. In a study of 263 candidates for OPAT, ID 
consultation resulted in optimization of the antibiotic treatment regimen or significant 
alterations in the patient’s assessment in 84% and 52%, respectively, of patients evaluated 
by OPAT physicians. Additionally, OPAT was determined to be unnecessary in 27% of 
patients evaluated, almost half of whom were deemed not to need any antibiotic therapy at 
all following discharge. 18 Although these studies demonstrate significant benefit to patients, 
few hospitals require ID consultation prior to discharge. In our study, only 22% of 
respondents indicated ID consultation was required to initiate OPAT. Our results suggest 
that there are significant opportunities for improvement in antibiotic stewardship through the 
use of routine ID consultation prior to OPAT initiation.
Additionally, our survey found that a wide variety of providers are responsible for 
monitoring and acting upon laboratory results for patients treated with OPAT, including 
inpatient ID physicians (reported by 63% of respondents), outpatient ID physicians (52% of 
respondents), patient primary care physicians (21% of respondents), and pharmacists (9% of 
respondents). While it is possible some variation may be attributable to different models of 
OPAT delivery,19 our findings suggest a lack of consensus regarding standard processes to 
ensure patients receive appropriate monitoring after hospital discharge. Only 26% of 
respondents indicated that their primary hospital or clinic had a specified provider or team 
whose primary purpose was to monitor patients receiving OPAT; it is possible that some 
clinical practices utilize various personnel to perform these duties even though it is not their 
primary role. Respondents reported many barriers to providing safe OPAT services. The 
lack of dedicated personnel was the single most common barrier reported by respondents. 
Although IDSA guidelines recommend a multidisciplinary team to coordinate care and 
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monitoring laboratory results, our study suggest that these recommendations may be poorly 
implemented in current practice.
Although prior surveys of infectious disease physicians suggest OPAT complications are 
common, there is limited data on the frequency of OPAT-related adverse events or hospital 
readmission.8 In a retrospective study of 302 courses of OPAT, significant adverse events 
were noted in 25%. Renal failure was the most common adverse event, occurring in 7% of 
OPAT courses.20 Among patients with osteomyelitis treated with OPAT, 5% developed 
some adverse event.21 This OPAT registry also demonstrated that 25.2% of patients treated 
with vancomycin experienced a vancomycin or IV-line related adverse event.22 Other 
reports have shown significant rates of decreased renal function, as high as 3.08 patients/
1,000 therapy-days among patients treated with select antibiotics.23 Hospital readmission 
due to complications of OPAT therapy occurs in 12–16% of patients.6, 24 In our study, 
respondents reported line occlusion or clotting, rash and nephrotoxicity occur commonly, 
although most believe there has been no change in the frequency of OPAT-related 
complications over the past 5 years. However, despite the frequency of these complications, 
fewer than one-quarter have systems to track the frequency of errors, adverse events or 
“near-misses” associated with OPAT. Given the widespread lack of reporting systems or 
registries, it is possible that error rates reported by respondents underestimate the true 
number of patients who experience harm while treated with OPAT.
Although weekly laboratory monitoring was most common for many antibiotics, our results 
demonstrated some variability in practice. Vancomycin use has become more common as 
methicillin-resistant Staphylococcus aureus rates have increased among hospitalized 
patients. Vancomycin-associated nephrotoxicity rates have been reported to vary widely 
from 5–35%.25 Clinical guidelines on vancomycin use suggest once weekly monitoring for 
hemodynamically stable patients26; however, these guidelines do not address the safety of 
high vancomycin dose strategies that target a trough concentration of 15–20 mg/L. A 
subsequent meta-analysis demonstrated an increased risk of nephrotoxicity among patients 
with vancomycin trough ≥ 15 mg/L compared to those with a trough < 15 mg/L (OR 2.67, 
95% CI, 1.95 – 3.65).27 Most respondents in our study report monitoring labs on a weekly 
basis for patients treated with vancomycin. However, more frequent laboratory monitoring, 
favored by 19% (86/445) of respondents, may allow for early identification and intervention 
in patients who develop nephrotoxicity.
This study has several limitations which may limit the generalizability of the results. 
Although we had >550 respondents, these respondents may not be representative of the 
entire infectious disease community. Additionally, a significant number of respondents 
indicated they were not required to be involved in the management of patients discharged on 
OPAT. Since our survey only targeted EIN members, it is possible that OPAT practices and 
complication rates identified in our survey are not representative of patients discharged on 
OPAT by other medical providers. Additionally, recall bias is an inherent limitation of 
surveys.
Although OPAT has been used for decades to successfully treat a wide array of infectious 
diseases, our study demonstrates there is tremendous variability in practice patterns among 
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physicians who provide OPAT services. With increasing focus on improving the quality of 
medical care and reducing hospital readmissions, standardization of OPAT practices has the 
potential to provide significant benefit to patients. In order to improve clinical outcomes, 
robust tracking systems or OPAT registries will need to be developed in order to further 
develop evidence-based practices and monitor individual patient outcomes.
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Figure 1. 
Number of respondents reporting perceived frequency of specified OPAT Complications
* DVT – Deep vein thrombosis.
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Figure 2. 
Number of respondents reporting perceived frequency of specified consequences of OPAT 
Complications
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